Table 7. MMP-9 SNPs genotype frequencies with respect to gender in POAG and PACG patients and unaffected controls.
|
Males |
Females |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Controls
n=71 (%) |
POAG
n=78 (%) |
p (χ2) |
PACG
n=40 (%) |
p (χ2) |
Controls
n=47 (%) |
POAG
n=34 (%) |
p (χ2) |
PACG
n=42 (%) |
p (χ2) |
|
| MMP-9 = c.-1562C>T | ||||||||||
|
CC |
42 (59.2) |
49 (62.8) |
0.43 (1.68) | 26 (65.0) |
0.22 (2.97) | 32 (68.1) |
21 (61.8) |
0.32 (2.25) | 30 (71.4) |
0.86 (0.28) |
|
CT |
24 (33.8) |
27 (34.6) |
14 (35.0) |
13 (27.7) |
13 (38.2) |
11 (26.2) |
||||
| TT | 5 (7.0) | 2 (2.6) | 0 (0.00) | 2 (4.2) | 0 (0.00) | 1 (2.4) | ||||
| MMP-9 = c.836A>G | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
AA |
24 (33.8) |
21 (26.9) |
0.28 (2.51) | 5 (12.5) |
0.009 (9.21) | 16 (34.0) |
5 (14.7) |
0.08 (4.88) | 10 (23.8) |
0.14 (3.86) |
|
AG |
33 (46.5) |
33 (42.3) |
18 (45.0) |
20 (42.6) |
15 (44.1) |
14 (33.3) |
||||
| GG | 14 (19.7) | 24 (30.8) | 17 (42.5) | 11 (23.4) | 14 (41.2) | 18 (42.9) | ||||